Last reviewed · How we verify
Ocriplasmin 125µg
Ocriplasmin is a recombinant microplasmin that enzymatically cleaves fibronectin and laminin in the vitreous to dissolve vitreous-retinal adhesions.
Ocriplasmin is a recombinant microplasmin that enzymatically cleaves fibronectin and laminin in the vitreous to dissolve vitreous-retinal adhesions. Used for Vitreomacular traction syndrome, Symptomatic diabetic macular edema with vitreous traction, Myopic traction maculopathy.
At a glance
| Generic name | Ocriplasmin 125µg |
|---|---|
| Also known as | Microplasmin |
| Sponsor | ThromboGenics |
| Drug class | Serine protease |
| Target | Fibronectin and laminin (extracellular matrix proteins) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ocriplasmin is a truncated form of human plasmin that selectively degrades extracellular matrix proteins at the vitreoretinal interface. By breaking down the protein scaffold that anchors the vitreous to the retina, it facilitates posterior vitreous detachment and relieves tractional forces that contribute to macular pathology. This mechanism allows non-surgical resolution of vitreoretinal adhesions in conditions like vitreomacular traction and macular holes.
Approved indications
- Vitreomacular traction syndrome
- Symptomatic diabetic macular edema with vitreous traction
- Myopic traction maculopathy
Common side effects
- Retinal detachment
- Retinal tear
- Photopsia (flashing lights)
- Floaters
- Conjunctival hemorrhage
Key clinical trials
- Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
- A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) (PHASE2)
- Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. (PHASE3)
- A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) (PHASE2)
- Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. (PHASE3)
- A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) (PHASE2)
- The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocriplasmin 125µg CI brief — competitive landscape report
- Ocriplasmin 125µg updates RSS · CI watch RSS
- ThromboGenics portfolio CI